Pharmeca.cz

When determining the maximum price and the reimbursement level of medicinal products in the Czech Republic, the principle of external price referencing (EPR) is applied. The principles of external price referencing in the Czech context are set out in Act No. 48/1997 Coll., on Public Health Insurance and on Amendments and Supplements to Certain Related Acts.

The foundation of this approach is the comparison of the ex-factory prices of a given medicinal product across EU countries, with the final maximum price in the Czech Republic derived based on these references. It is important to note that EPR conditions and methodologies vary across the EU and a uniform approach has not yet been adopted. Each country has its own specific rules and lists of countries it references in its EPR system.

To support understanding, we have created an interactive map that visualizes the countries involved in the EPR system as applied in the Czech Republic. This tool provides a quick overview of which countries are considered when determining the maximum price and the reimbursement level of medicinal products in the Czech setting.

🔍 Map features:

• Display of countries used as reference when determining reimbursement levels
• Overview of national price databases
• Distinction between countries used in the reference basket for the manufacturer’s maximum price
• Clear color coding for easy navigation

This map is a useful tool for:

• Professionals in the pharmaceutical industry
• Health policy analysts
• Pricing and reimbursement regulators
• And anyone interested in the dynamics of European pharmaceutical pricing strategies

👉 The interactive map is available here